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Purpose
In 2010, the World Health Organization categorized L-cell type neuroendocrine tumors
(NETs) as tumors of uncertain malignancy, while all others were classified as malignant.
However, the diagnostic necessity of L-cell immunophenotyping is unclear, as are tumor
stage and grade that may guide diagnosis and management. To clarify the predictive 
markers of rectal neuroendocrine neoplasms (NENs), 5- and 10-year overall survival (OS)
was analyzed by pathological parameters including L-cell phenotype.
Materials and Methods
A total of 2,385 rectal NENs were analyzed from our previous multicenter study and a subset
of 170 rectal NENs was immunophenotyped.
Results
In univariate survival analysis, tumor grade (p < 0.0001), extent (p < 0.0001), size 
(p < 0.0001), lymph node metastasis (p=0.0063), and L-cell phenotype (p < 0.0001)
showed significant correlation with the prognosis of rectal NENs; however, none of these
markers achieved independent significance in multivariate analysis. The 10-year OS of 
tumors of NET grade 1, < 10 mm, the mucosa/submucosa was 97.58%, 99.47%, and
99.03%, respectively. L-Cell marker, glucagon II (GLP-1&2), with a cut off score of > 10, is
useful in defining L-Cell type. In this study, an L-cell immunophenotype was found in 83.5%
of all rectal NENs and most, but not all L-cell type tumors were NET G1, small (< 10 mm)
and confined to the mucosa/submucosa.
Conclusion
From these results, the biological behavior of rectal NENs does not appear to be determined
by L-cell type alone but instead by a combination of pathological parameters. 
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Introduction
A remarkably increasing incidence of gastroentero-pancre-
atic neuroendocrine neoplasms has been reported over the
past several decades throughout the world [1-10]. In our 
previous nationwide study, we showed that the incidence
has also been increasing in Korea over the last decade [3].
The most significant increase was found in the rectum, 
particularly for well-differentiated neuroendocrine tumors
(NETs). In fact, the most common neuroendocrine neoplasm
(NEN) site in Korea is the rectum, similar to that reported in
Japan [7]. Recently the Surveillance Epidemiology and End
Result (SEER) data of United States [5] and data of  European
Neuroendocrine Tumor Society (ENETS) [11] also described
remarkable increases in the incidence of rectal NETs, 
although the most common site in western countries remains
the small intestine [6]. The increasing incidence of rectal
NETs in Korea may relate to ascertainment bias from an 
increasing awareness of this tumor and improved availabil-
ity of endoscopy, although a true increase in incidence 
cannot be excluded. Rectal NETs are usually small and often
incidentally discovered on endoscopy. Simple endoscopic 
excision is the typical mode of treatment. The prognosis for
this type of local disease is known to be excellent [5,11]; 
however, confusion arises in cancer registries and over med-
ical insurance compensation, particularly in relation to the
2010 World Health Organization (WHO) classification 
recommendations. 
The WHO updated the classification of these tumors in
2010 and categorized them all as malignant, except for L-cell
type and tubular NETs [12], which were designated as 
having uncertain malignant behavior. L-Cell NENs that are
glucagon like peptide (GLP) or PP/PYY producing tumors
have been approved for classification as uncertain malig-
nancy by the International Agency for Research on Cancer
(IARC)/WHO Committee for International Classification of
Disease for Oncology, third edition (ICD-O3) in 2010 [12].
Coding of these tumors according this classification greatly
affects the results of cancer registration and implicates L-cell
phenotyping of NENs for pathology reports. Potential issues
are raised because the diagnostic criteria for L-cell phenotyp-
ing are not clear-cut and the relation to other well-known
prognostic factors, such as tumor grade, size, and depth 
remain unclear. As a practical point, this difference in classi-
fication has created confusion in the diagnosis, management,
and coding of small rectal NETs that are < 10 mm, have low
mitoses (WHO G1, < 2 mitosis/10 high-power field [HPF]),
confined to the mucosa-submucosa and lacking additional
risk factors. These lesions were formerly categorized as 
benign by the 2000 WHO system; however they should be
classified as malignancy if it is not confirmed as L-cell type
by the 2010 WHO classification. However, the National Com-
prehensive Cancer Network (NCCN) clinical practice guide-
lines recommend simple excision of small NETs [13],
irrespective of lymphatic invasion or cell type of origin. Lee
et al. [14] recently reported that 79% of rectal NETs were 
immunohistochemically defined as L-cell type but they
showed no clinical significance for L-cell type in their 
reported rectal NETs. 
In our previously published large nationwide multicenter
study, rectal NENs showed the best prognosis among 
all gastroenteropancreatic (GEP)-NENs. However, it was 
unclear whether or not cell of origin affected the prognosis
because information on cell type was unavailable in that
study.
Here questions arise about the necessity of L-cell type 
immunophenotyping in daily practice for better prediction
of patient’s prognosis. In addition, it is unclear whether small
rectal (WHO G1) NETs by the 2010 WHO classification
should be categorized as malignant, if not of L-cell type. To
investigate these uncertainties, we analyzed the prognostic
significance of L-cell phenotype in rectal NETs, along with
previously known factors affecting biologic behavior, to 
assess the validity of malignancy criteria of rectal NENs.
Materials and Methods
1. Patient selection and pathological parameters
Rectal NENs from the nationwide Korean multicenter data
of our previous publication were studied [3]. For survival
analyses, follow-up data were collected from the National
Cancer Registration Center. This protocol was reviewed and
approved by the Institutional Review Board of Kangbuk
Samsung Hospital (approval No. KBC13067).
Inclusion criteria required pathologically confirmed rectal
NENs from January 1, 2000, to December 31, 2009. Exclusion
criteria included adenocarcinomas with focal neuroen-
docrine differentiation. If a NEN underwent subsequent 
excision or surgical resection following an initial biopsy, the
biopsy report from the same case was excluded in order 
to eliminate duplication of cases. Pathologic parameters 
analyzed included tumor size, grade, extent, lymph node
metastasis, and patient survival. Tumor grading was based
on mitotic count or Ki-67 labeling index as NET G1 or NET
G2 recommended by the 2010 WHO classification [12]. 
However, neuroendocrine carcinoma (NEC) was diagnosed
for poorly differentiated tumors with high grade small or
large cell cytology with organoid features and neuroen-
docrine immunophenotyping, regardless of the mitotic
Jin Hee Sohn, Prognostic Impact of L-Cell Typing in Rectal NENs
VOLUME 47  NUMBER 4  OCTOBER  2015 815
counts. The extent of tumor was evaluated according to the
2010 American Joint Committee on Cancer (AJCC) tumor
staging manual [15]. Lymph node metastasis was coded as
either present or absent. Maximum tumor size was assessed
in mm’s and grouped by 5-mm intervals (1, 1-4 mm; 2, 5-9
mm; 3, 10-14 mm; 4, 15-20 mm; and 5, > 20 mm).
2. Immunohistochemistry for L-cell phenotype 
A total of 170 rectal NENs with available paraffin blocks
and follow-up information were selected from among the 
nationwide data due to the limitation of the resource. To 
assess the relation of L-cell phenotype with other pathologic
parameters and biological behavior, we included as many
cases treated by surgical resection with lymph node dissec-
tion as possible, regardless of tumor grade and added cases
of NET G1 treated by local excision. For comparison, 50 
gastric NENs, 32 small intestinal NENs, and 22 colonic NENs
were also evaluated. An auto-stainer (Benchmark XT, 
Ventana Medical Systems, Roche, Tucson, AZ) minimized
technical and sampling error. The UltraView Universal DAB
Detection Kit was used for immunohistochemical (IHC)
staining. Three different primary antibodies were used for
L-cell immunophenotyping: glucagon I (GLP-1, Roche),
glucagon II (GLP-1&2, LifeSpan Bioscience, Seattle, WA), and
PYY (Sigma, St. Louis, MO). The steps are briefly described
as follows. Paraffin-embedded tissue sections from well 
representative blocks were deparaffinized with xylene and
rehydrated through graded alcohol solutions. Antigen 
retrieval consisted of warming the slide to 75°C (4 minutes),
and application of cell conditioning solution No. 1 (60 min-
utes). Endogenous peroxidase was blocked by applying UV
inhibitor (4 minutes). After washing with reaction buffer, 
primary antibody was applied (2 hours) in a autostainer.
Slides were then rinsed with reaction buffer and added one
drop each of HRP UNIV MULT, DAB, and DAB H2O2 (Ven-
tana Medical Systems, Roche) (8 minutes each). Slides were
then treated with one drop of COPPER (4 minutes) before
counterstaining with hematoxylin (4 minutes). Interpretation
of IHC staining for glucagon I, glucagon II, and PYY was 
separately evaluated based on the staining intensity (1,
weaker than normal control; 2, strong as control) and distri-
bution (% of positive cells). And then they were multiplied
for an immunoscore (0-200), that was grouped as 0 (< 10), 1
(10-50), 2 (51-100), or 3 (> 100). The results were interpreted
as negative (score group 0) or positive (score groups 1-3). The
immunostaining results were evaluated independently by
two pathologists blinded to the patients’ clinical and patho-
Table 1. The number of rectal NENs from available recorded information by the pathological parameter collected from the
nationwide multicenter data
Clinicopahtological parameter No. of cases with available information (%) Total 
Histologic classification (2000 WHO) WDET 1,620 (93.37) 1,732
WDEC 57 (3.29)
PDEC 45 (2.59)
MEEC 10 (0.58)
Grade (2010 WHO) NET G1 906 (87.28) 1,038
NET G2 66 (6.36)
NEC 66 (6.36)
Extent Mucosa-submucosa 1,582 (92.62) 1,708
Proper muscle 33 (1.93)
Subserosa 44 (2.58)
Serosa 12 (0.70)
Adjacent organ invasion 4 (0.23)
Distant metastasis 33 (1.93)
Size (mm) 1-4 547 (38.31) 1,428
5-9 604 (42.30)
10-14 150 (10.50)
15-20 52 (3.64)
> 20 75 (5.25)
WHO, World Health Organization; WDET, well-differentiated endocrine tumor; WDEC, well-differentiated endocrine carci-
noma; PDEC, poorly-differentiated endocrine carcinoma; MEEC, mixed exo-endocrine carcinoma; NET G1, neuroendocrine
tumor grade 1; NET G2, neuroendocrine tumor grade 2; NEC, neuroendocrine carcinoma.
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logic information. L-Cell type was determined if the sample
was immunohistochemically positive (immunoscore > 10)
for one or more markers [14].
3. Statistical analysis
Data were presented as numbers (%) for categorical vari-
ables. In survival analysis, we excluded cases that only 
underwent small biopsy. To estimate the association between 
eligible variables and mean overall survival time, the 
Kaplan-Meier test was applied together with the log-rank
test for comparison of various groups. The 5- and 10-year
overall survival rates in each parameter were evaluated. A
Cox proportional hazard regression was performed adjust-
ing for gender and age to determine the independent prog-
nostic factor and the significance was determined at 95%
confidence level. PASW ver. 18.0 (SPSS Inc., Chicago, IL) was
used for statistical analyses. A p-value of < 0.05 was consid-
ered statistically significant. 
Results
1. Pathological characteristics of rectal NENs in Korea 
Among 4,951 GEP-NENs in our previous nationwide data
of Korea, there were 2,385 rectal NENs (48.17%) [3]. The
mean age of the rectal NEN patients was 52.13±11.77 years
old and the sex ratio (male:female) was 1.58:1. The patholog-
ical parameters are shown in Table 1. Follow-up data were
available in only 1,621 patients and the mean survival dura-
tion was 50.93±30.16 months. Among the total rectal NENs,
lymph node metastasis was confirmed in 76 cases (3.19%);
however, most tumors were treated by endoscopic mucosal
resection because they were small WHO NET G1 tumors
confined to the mucosa-submucosa, in which case lymph
nodes were not resected or examined.
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Fig. 1. Five- and 10-year overall survival rates in patients with rectal neuroendocrine neoplasms (NENs) according to the
grade (A), size group (B), lymph node (LN) metastasis (C), extent (D) and L-cell type (E). Rectal neuroendocrine tumors
(NETs) with < 2 mitoses per 10 high-power field’s (World Health Organization G1), confined to the mucosa-submucosa,
with no lymph node metastases, and of L-cell type showed excellent prognosis. In particular, 10-year survival rate of NETs
G1 confined to mucosa-submucosa was more than 99%.
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2. Prognostic significance of pathological parameters in 
rectal NENs 
In survival analysis, mean survival time according to the
tumor grade was 74.01±0.27 months for G1, 43.14±1.62
months for G2, and 24.85±2.28 months for G3 (p < 0.0001).
The tumor extent showed prognostic significance (p < 0.0001)
and mean survival time was the longest in tumors confined
to the mucosa and submucosa (66.05±0.15 months) and
shortest in tumors with adjacent organ invasion (22.08±3.60
months) while that in tumors with distant metastasis was
35.07±2.55 months (p < 0.0001). The size of tumor was signif-
icantly correlated with patient’s survival and the size group
of 10-14 mm showed the longest mean survival time
(64.90±0.66 months) in contrast to the shortest in the size
group of 15-20 mm (26.08±0.57) (p < 0.0001). Mean survival
time according to lymph node metastasis was 33.66±1.81
months for the node positive group, in contrast to 71.35±2.90
months for the negative group (p=0.0063). Five- and 10-year
OS according to the pathological parameters are shown in
Fig. 1. The 10-year OS of patients with tumors < 10 mm was
more than 99%, while that of patients with tumors ! 20 mm
was 35.5%. In multivariate analysis, none of the variables of
tumor size, extent, grade, or lymph node metastasis showed
independent prognostic significance. 
Lymph node metastasis showed significant correlation
with tumor grade (p=0.0069), extent (p=0.0273), and size
(p=0.0039). Among 774 NET showing G1 and < 10 mm, eight
cases were confirmed as having lymph node metastasis. 
Although the lymph node negative group showed signifi-
cantly better survival compared to node positive patients
when all samples were analyzed (p < 0.0063), there was no
significant survival difference between them if cases of 
NET G1 and G2 were selectively analyzed (mean survival
time±standard deviation: 40.49±2.48 months for positive
group and 74.6 months for negative group, p=0.4830) (Fig. 2). 
3.  Expression of L-cell markers and its prognostic signifi-
cance in rectal NENs
Three L-cell markers (glucagon I, glucagon II, and PYY)
clearly demonstrated L-cells scattered in the normal mucosa
which served as an internal control (Fig. 3). The prevalence
of L-cell type, defined by one or more markers with an 
immunoscore > 10, was 83.5% among all rectal NENs. L-Cell
tumors with one marker positivity made up 27%, two mark-
ers 39.86%, and all three markers 35.57%. Among 104 
non-rectal NENs examined, 0/50 patients with gastric NENs
(0%), 3/27 patients with duodenal NENs (11.11%), and 6/18
patients with colonic NENs (33.33%) demonstrated an L-cell
phenotype. The immunoscores of the three different markers
were significantly correlated with each other (Table 2). 
In univariate analysis, all three markers showed significant 
correlation with prognosis (p=0.0018 for glucagon I, 
p < 0.0001 for glucagon II, and p=0.0209 for PYY), however
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Fig. 2. Survival analysis according to lymph node metastasis (LN_Mets) in all samples (A), and neuroendocrine tumors
(NET) G1 and G2 (B). LN_Mets was significantly related with poor prognosis in all rectal neuroendocrine neoplasms exam-
ined (p < 0.0001), but it was not if NET G1 and G2 tumors were selectively analyzed (p=0.4830).
Table 2. Correlation analysis of immunoexpression 
between the three L-cell markers
Glucagon-I Glucagon-II PYY
Glucagon-I 1.00000 - -
Glucagon-II 0.77165a) 1.00000 -
PYY 0.42458a) 0.42876a) 1.00000
a)Pearson correlation coefficient.
only glucagon II was a significant prognostic factor in mul-
tivariate analysis of three markers (p=0.0232; hazard ratio
[HR], 3.668; 95% confidence interval [CI], 1.194 to 11.268). 
Immunoscore was divided into four groups of increasing
positivity from 0-3 and the 5-year OS were 59.48%, 82.47%,
95.24%, and 100%, respectively. Survival curves according 
to the immunoscore groups are shown in Fig. 4. Five- and 
10-year OS of score group 1 were significantly better than
those of the negative tumor (score group 0). The distribution
of the L-cell score group in each histologic grade, size, extent,
and node metastasis of NENs is shown in Fig. 5. Most L-cell
phenotype were NET G1, small and limited to mucosa and
submucosa, but few were NEC, large size or even node 
positive tumors. 
Results of clinicopathologic analysis in relation to L-cell
phenotype are shown in Table 3. The immunoscore of L-cell
markers showed inverse correlation with tumor size (Pear-
son correlation coefficient, –0.45889). Among the pathologic
parameters, tumor grade (p < 0.0001) and extent (p < 0.0001)
of L-cell tumor significantly differed from those of non–
L-cell type tumor, but lymph node metastasis (p=0.1453) did
not. Lymph node metastasis was observed in 33 out of 46 
L-cell type tumors (71.74%) and in 16 out of 18 non–L-cell 
tumors (88.89%) among 64 cases in which the lymph node
evaluation was performed. L-Cell phenotype was more 
common in NET G1, tumor confined to the submucosa and
small size (< 1 cm).
Discussion
Among all NENs in the body, rectal NETs are known to
have the best prognosis, with a 5-year survival rate of 88.3%
for all stages [2] and 90% for localized tumors with increased
survival rates over time [1]. WHO classification based mitotic
rate (grade) and stage (size and extent) are well known to
predict patient’s survival but none are independent factors
[16]. The 2010 WHO categorized L-cell type tumors, as 
uncertain malignancies, while all other NENs were classified
as malignant. However, no concrete criteria were provided
for defining L-cell type NET by histology or immunopheno-
typing and none clearly exist in the literature either. The
defining L-cell type of rectal NENs by IHC stain also needs
clarification as do other prognostic factors that may guide 
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Fig. 3.  Patterns and distribution of immunohistochemical expression of L-cell markers. The arrows (A) indicate L-cell marker
cytoplasmic staining in normal endocrine cells of associated benign rectal mucosa that serves as a positive control. L-Cell 
immunohistochemical staining of rectal neuroendocrine neoplasms (NENs) was either focal/localized (B, C) or diffuse (D).
L-Cell NEN type is defined by one or more positive markers (immunoscore > 10) (A-D, "400).
A B
C D
diagnosis and management. In relation to cancer registry
data and medical insurance compensation, ICD-O behavior
code “/1” means low malignant potential or uncertain 
malignant potential, and behavior code “/3” means frank
malignancy. Therefore, dividing malignant tumors with low
malignant potential (/1), very good prognosis and long 
survival from frankly malignant tumors (/3) is important. 
In this study, we analyzed the 5- and 10-year OS of rectal
Table 3. Clinicopathologic analysis of rectal NENs in relation to L-cell phenotype
Clinicopathologic parameter No. of cases Non–L-cell type L-Cell type p-value
Grade NET G1 113 (64.42) 4 (3.54) 109 (96.46) < 0.0001
NET G2 21 (12.88) 1 (4.76) 20 (95.24)
NEC 29 (17.79) 17 (58.62) 12 (41.38)
Total 163 (100) 22 (13.50) 141 (86.50)
Extent Mucosa/submucosa 90 (63.38) 3 (3.33) 87 (96.67) < 0.0001
Proper muscle 13 (9.15) 2 (15.39) 11 (84.61)
Subserosa 24 (16.90) 8 (33.33) 16 (66.67)
Serosa 6 (4.23) 3 (50.00) 3 (50.00)
Adjacent organ 2 (1.41) 1 (50.00) 1 (50.00)
Distant metastasis 7 (4.93) 3 (42.86) 4 (57.14)
Total 142 (100) 20 (14.08) 122 (85.92)
Size 141 (100) 33.6905±26.0809 12.4417±12.5830 < 0.0001
LN metastasis Positive 49 (76.56) 16 (32.65) 33 (67.35) 0.1453
Negative 15 (23.44) 2 (13.33) 13 (86.67)
Total 64 (100) 18 (28.13) 46 (71.87)
Values are presented as number (%) or mean±standard deviation. n, number of cases with available data; NET G1, neuroen-
docrine tumor grade 1; NET G2, neuroendocrine tumor grade 2; NEC, neuroendocrine carcinoma (G3); LN, lymph node.
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2: p=0.0059; HR, 0.120; 95% CI, 0.026 to 0.544; immunoscore group 3: p # 0.0001; HR, 0.051; 95% CI, 0.016 to 0.205).
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NETs in relation to the pathological parameters, including
L-cell typing. A full of 80.61% (n=1,151) of rectal NENs were
less than 10 mm and these patients had an excellent progno-
sis with 10-year OS of more than 99%, if the tumor was NET
G1 and confined to the mucosa-submucosa (small NET). 
Although univariate analysis showed significant prognostic
significance of tumor grade, size, extent, lymph node metas-
tasis and L-cell type, no independent prognostic factors were
identified among them in multivariate analysis. The
Colonoscopy Study Group of the Korean Society of Colo-
proctology reported lymph node metastasis in 5.1% (21 out
of 414 rectal NETs) and was related to tumor size [17]. Lee et
al. [14] reported that 6/151 patients with rectal NETs (4%)
from 4 to 9 mm in diameter had lymph node metastasis;
however patient outcome was not provided. Yamagishi et al.
[18] also reported that lymph node metastasis was found in
8/20 patients with surgically resected rectal NETs, smaller
than 10 mm, but no disease-related deaths were reported
with a mean follow-up period of 68 months. In contrast, Jern-
man et al. [16] found that none of 61 patients with NET G1
had metastatic disease during follow-up (mean, 124 months).
In a Japanese report, metastasis was significantly correlated
with the tumor size, importantly, tumors less than 10 mm
and confined to the mucosa-submucosa without vessel inva-
sion did not show metastasis [19]. Although cases of small
rectal carcinoid (< 10 mm) accompanied by multiple liver
metastases have rarely been reported in the literature [20],
but the pathological characteristics of these tumor, such as
grade and extent are not clearly described. In the survival
analysis of our data, 5- and 10-year OS were more than 99%
if the tumor size was less than 10 mm, irrespective of lymph
node metastasis. As mentioned, lymph node metastasis in
patients with NET G1 and G2 did not show any prognostic
significance in the survival analysis, however it is very diffi-
1
9
4 7
17
7
2 34
21
17
71
A
No
. o
f c
as
es
80
60
40
20
0
NET G1 
(n=113)
NET G2
(n=21)
NEC
(n=29)
Grade
2
11
6
26
1
4 3
10
4 3 3
21
B
No
. o
f c
as
es
30
25
20
15
10
5
0
1-4 mm
(n=31)
5-9 mm
(n=45)
10-14 mm
(n=18)
2
4
2 3
15-20 mm
(n=11)
12 13
4
7
> 20 mm
(n=36)
Size
Score group 0
Score group 1
Score group 2
Score group 3
2 4
7
0
8 6 10
03
10
77
0
C
No
. o
f c
as
es
90
75
60
45
30
15
0
Mucosa and
submucosa
(n=90)
Propermuscle
(n=13)
Subserosa
(n=24)
3 1 2 0
Serosa
(n=6)
1 1 0 0
Adjacent organ
(n=2)
3 3 1 0
Distant
metastasis
(n=7)
Extent
2
4
7
2
16
13
7
13
D
No
. o
f c
as
es
20
15
10
5
0
LN positive
(n=49)
LN negative 
(n=15)
LN metastasis
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cult to determine the true incidence of lymph node metasta-
sis in small NET because most of these NET were treated by
endoscopic mucosal resection without lymph node dissec-
tion. We disagree with the 2000 WHO classification consid-
ering well-differentiated NETs as benign, because all NETs
have malignant potential of varying degree as seen in our
data. On the other hand, we reconfirm the excellent progno-
sis for patients with small rectal NETs, showing that this 
series is representative of prior literature and not biased by
the Korean nationality of this study population. Therefore
we believe that NETs have distinguished biological charac-
teristics from NEC, frank malignancy (ICD-O code /3), 
although their pathogenetic mechanism is not yet clear. 
In this study, to define the L-cell phenotype by immuno-
histochemistry, we compared three primary antibodies 
(2 glucagons and 1 PYY). The glucagon I primary antibody
can detect the GLP-1 but the glucagon II can detect both GLP-
1 and 2. Gastric and duodenal NENs were almost all negative
for all L-cell markers (except for 3 duodenal NENs), while
33.33% of non-rectal, colonic NENs and 83.7% of rectal NENs
were defined as L-cell type. Even though the immunoscores
of the three markers were significantly correlated with each
other and all were  prognostically significant by univariate
analysis (p=0.0018, p < 0.0001, and p=0.0209, respectively),
the patterns of expression were heterogeneous across cases
(Fig. 3). In multivariate analysis of three markers, only
glucagon II was prognostically significant (p=0.0232; HR,
3.669; 95% CI, 0.094 to 11.269). Immunoscoring was divided
into four groups of increasing positivity from 0-3 and the 
5-year OS were 48.33%, 91.47%, 94.44%, and 95.29%, respec-
tively. These survival data strongly support the reliability of
using a cutoff score group of more than 0 (immunoscore 
< 10) for these three markers for defining the L-cell type. Lee
et al. [14] reported that the L-cell type was 79% in rectal NETs
with varying immunoscores of 1-300. They divided the 
intensities into three groups while we divided them into two.
We evaluated the intensity of immunoexpression by compar-
ing tumor cells to normal L-cells in the non-neoplastic 
mucosa, classifying expression as weaker than or equal to
that of L-cells in normal mucosa, because L-cells in normal
mucosa showed uniform strong staining. Differences in 
L-cell tumor incidence may be related to use of different 
L-cell markers and absence of a standardized definition. In
this study, we described the differences in immunoexpres-
sion patterns across L-cell markers. We found that glucagon
II, which detects GLP-1 and GLP-2, was better than glucagon
I and PYY because of the highest hazard ratio in multivariate
analysis. In NET G1 and G2 tumors, L-cell type made up
96.56% and 95.24%, respectively, and 96.7% of mucosa/sub-
mucosa tumors and 92.1% of tumors < 1 cm. These findings
may support that 2010 WHO classification describes 
L-cell type as uncertain malignancy/low malignant potential
(ICD-O code /1).
Although the univariate analysis suggested size, grade, 
extent, lymph node metastasis, and L-cell phenotype as 
significant prognostic factors, multivariate analysis failed to
show that only a single factor may not adequately predict
prognosis. This also validates the conclusion that the 
suggested combined criteria are suitable for assessment of
the biological behavior of rectal NENs. Therefore, in practice,
we recommend perform IHC staining for L-cell markers for
phenotyping of rectal NET and L-cell type best define classi-
fication as uncertain malignancy or low malignant potential
(ICD-O code /1) [21,22] as indicated by the 2010 WHO 
classification if it is small (< 10 mm), G1 (< 2 mitoses per 
10 HPF's), and with mucosa/submucosa-limited invasion. 
Conclusion
We reconfirm the excellent prognosis for patients with 
rectal NET G1 if the tumor size was less than 10 mm and 
confined to the mucosa/submucosa, irrespective of lymph
node metastasis. L-Cell type made up 96.56% of NET G1,
96.7% of mucosa/submucosa tumors, and 92.1% of tumors 
< 1 cm. These findings may support that 2010 WHO classifi-
cation describes L-cell type as uncertain malignancy/low
malignant potential (ICD-O code /1). Because multivariate
analysis failed to show that only a single factor can ade-
quately predict patient’s prognosis, we suggest combined 
criteria are suitable for assessment of the biological behavior
of rectal NENs.
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